The lipid phosphatase SHIP2 controls insulin sensitivity

被引:0
|
作者
Serge Clément
Ulrike Krause
Florence Desmedt
Jean-François Tanti
Jens Behrends
Xavier Pesesse
Takehiko Sasaki
Joseph Penninger
Margaret Doherty
Willy Malaisse
Jacques E. Dumont
Yannick Le Marchand-Brustel
Christophe Erneux
Louis Hue
Stéphane Schurmans
机构
[1] IRIBHN,Amgen Institute/Ontario Cancer Institute Department of Medical Biophysics and Immunology
[2] IBMM,undefined
[3] ICP,undefined
[4] Hormone and Metabolic Research Unit,undefined
[5] IRIBHN,undefined
[6] Campus Erasme,undefined
[7] INSERM E9911,undefined
[8] Faculté de Médecine ,undefined
[9] University of Toronto,undefined
[10] Laboratoire de Médecine Expérimentale,undefined
[11] Campus Erasme,undefined
来源
Nature | 2001年 / 409卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Insulin is the primary hormone involved in glucose homeostasis, and impairment of insulin action and/or secretion has a critical role in the pathogenesis of diabetes mellitus. Type-II SH2-domain-containing inositol 5-phosphatase, or ‘SHIP2’, is a member of the inositol polyphosphate 5-phosphatase family1. In vitro studies have shown that SHIP2, in response to stimulation by numerous growth factors and insulin, is closely linked to signalling events mediated by both phosphoinositide-3-OH kinase and Ras/mitogen-activated protein kinase2,3,4,5. Here we report the generation of mice lacking the SHIP2 gene. Loss of SHIP2 leads to increased sensitivity to insulin, which is characterized by severe neonatal hypoglycaemia, deregulated expression of the genes involved in gluconeogenesis, and perinatal death. Adult mice that are heterozygous for the SHIP2 mutation have increased glucose tolerance and insulin sensitivity associated with an increased recruitment of the GLUT4 glucose transporter and increased glycogen synthesis in skeletal muscles. Our results show that SHIP2 is a potent negative regulator of insulin signalling and insulin sensitivity in vivo.
引用
收藏
页码:92 / 97
页数:5
相关论文
共 50 条
  • [31] MicroRNA-205 regulates the lipid phosphatase SHIP2 in keratinocytes and may function as an oncogene in squamous cell carcinomas
    Lavker, R. M.
    Yu, J.
    Oliveira-Fernandes, Mx
    Collyer, J.
    Fatima, A.
    Getsios, S.
    Ryan, D. G.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2008, 128 : S30 - S30
  • [32] Crosstalk between metabolic and oncogenic pathways via SHIP2 inositol phosphatase
    Prasad, Nagendra
    Tandon, Manish
    Camarillo, Ignacio
    CANCER RESEARCH, 2008, 68 (09)
  • [33] Structural basis for interdomain communication in SHIP2 providing high phosphatase activity
    Le Coq, Johanne
    Camacho-Artacho, Marta
    Velazquez, Jose Vicente
    Santiveri, Clara M.
    Gallego, Luis Heredia
    Campos-Olivas, Ramon
    Dolker, Nicole
    Lietha, Daniel
    ELIFE, 2017, 6
  • [34] 5′-inositol phosphatase 2 (SHIP2) is over-expressed in endometrial cancer
    Sever, M
    Tandon, M
    Prasad, N
    Badve, S
    LABORATORY INVESTIGATION, 2006, 86 : 195A - 195A
  • [35] 5′-inositol phosphatase 2 (SHIP2) is over-expressed in endometrial cancer
    Sever, M
    Tandon, M
    Prasad, N
    Badve, S
    MODERN PATHOLOGY, 2006, 19 : 195A - 195A
  • [36] Temporospatial effects of endothelium specific inhibition of SHIP2 on nitric oxide bioavailability and whole body insulin sensitivity
    Gage, M. C.
    Viswambharan, H.
    Cubbon, R.
    Imrie, H.
    Galloway, S.
    Yuldasheva, N.
    Smith, J.
    Schurmans, S.
    Wheatcroft, S.
    Kearney, M.
    DIABETIC MEDICINE, 2014, 31 : 10 - 11
  • [37] Ebselen enhances insulin sensitivity by inhibiting SHIP2 and protects diabetic mice from oxidative stress and inflammation
    Polianskyte-Prause, Z.
    Tolvanen, T. A.
    Lindfors, S.
    Kon, K.
    Hautala, L. C.
    Wang, H.
    Wada, T.
    Tsuneki, H.
    Sasaoka, T.
    Lehtonen, S.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S220 - S221
  • [38] Molecular cloning and characterization of rat SHIP2 in the regulation of insulin action
    Sasaoka, T
    Ishihara, H
    Wada, T
    Hori, H
    Kobayashi, M
    DIABETES, 1999, 48 : A60 - A60
  • [39] Metformin ameliorates peripheral insulin resistance by inhibiting the activity of SHIP2
    Lehtonen, S.
    Polianskyte-Prause, Z.
    Tolvanen, T. A.
    Lindfors, S.
    Latvala, M.
    Wang, H.
    Dash, S. N.
    Berg, M.
    Dumont, V.
    Groop, P. -H.
    Wahala, K.
    Tienari, J.
    DIABETOLOGIA, 2016, 59 : S243 - S243
  • [40] Drugs targeting SHIP2 demonstrate potent antiproliferative effects irrespective of SHIP2 inhibition
    El Sayed, Abdulrahman
    Gomes, Nelson
    Czerwinska, Areta
    Azzi, Abdelhalim
    LIFE SCIENCES, 2024, 357